Clinical Trial Update: A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG) [Phase 3]

View source ↗

Summary

This Phase 3 open-label crossover trial evaluating self-administration of Rozanolixizumab in generalized myasthenia gravis has completed, with results posted on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis Generalized

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: COMPLETED | Results posted: 2025-05-07